Get the Stockscreener App
2.73
3.41%
+0.09
After Hours:
2.82
0.09
+3.30%
LAVA Therapeutics NV stock is currently priced at $2.73, with a 24-hour trading volume of 49,922.
It has seen a +3.41% increased in the last 24 hours and a -32.26% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $2.67 pivot point. If it approaches the $2.82 resistance level, significant changes may occur.
Previous Close:
$2.64
Open:
$2.7
24h Volume:
49,922
Market Cap:
$71.77M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-1.7727
EPS:
-1.54
Net Cash Flow:
$5.89M
1W Performance:
+0.74%
1M Performance:
-32.26%
6M Performance:
+118.40%
1Y Performance:
+80.79%
1D Range:
$2.68
$2.8199
52W Range:
$1.131
$6.47
LAVA Therapeutics NV Stock (LVTX) Company Profile
Name
LAVA Therapeutics NV
Sector
Industry
Phone
31 630 00 30 35
Address
Yalelaan 60, Utrecht
LAVA Therapeutics NV Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
LAVA Therapeutics NV Stock (LVTX) Latest News
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
GlobeNewswire Inc.
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Benzinga
LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
GlobeNewswire Inc.
LAVA Therapeutics NV Stock (LVTX) Financials Data
LAVA Therapeutics NV (LVTX) Revenue 2024
LVTX reported a revenue (TTM) of $9.06 million for the quarter ending September 30, 2023, a -49.17% decline year-over-year.
LAVA Therapeutics NV (LVTX) Net Income 2024
LVTX net income (TTM) was -$50.39 million for the quarter ending September 30, 2023, a -99.88% decrease year-over-year.
LAVA Therapeutics NV (LVTX) Cash Flow 2024
LVTX recorded a free cash flow (TTM) of $5.89 million for the quarter ending September 30, 2023, a +114.86% increase year-over-year.
LAVA Therapeutics NV (LVTX) Earnings per Share 2024
LVTX earnings per share (TTM) was -$1.92 for the quarter ending September 30, 2023, a -86.41% decline year-over-year.
About LAVA Therapeutics NV
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
1.53%
3.38%
Cap:
|
Volume (24h):